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Abstract
Background: Systemic infection leads to generation of inflammatory mediators that result in metabolic and
behavioural changes. Repeated or chronic systemic inflammation leads to a state of innate immune tolerance: a
protective mechanism against overactivity of the immune system. In this study, we investigated the immune
adaptation of microglia and brain vascular endothelial cells in response to systemic inflammation or bacterial
infection.
Methods: Mice were given repeated doses of lipopolysaccharide (LPS) or a single injection of live Salmonella
typhimurium. Inflammatory cytokines were measured in serum, spleen and brain, and microglial phenotype studied
by immunohistochemistry. To assess priming of the innate immune response in the brain, mice were infected with
Salmonella typhimurium and subsequently challenged with a focal unilateral intracerebral injection of LPS.
Results: Repeated systemic LPS challenges resulted in increased brain IL-1β, TNF-α and IL-12 levels, despite
attenuated systemic cytokine production. Each LPS challenge induced significant changes in burrowing behaviour.
In contrast, brain IL-1β and IL-12 levels in Salmonella typhimurium-infected mice increased over three weeks, with
high interferon-γ levels in the circulation. Behavioural changes were only observed during the acute phase of the
infection. Microglia and cerebral vasculature display an activated phenotype, and focal intracerebral injection of LPS
four weeks after infection results in an exaggerated local inflammatory response when compared to non-infected
mice.
Conclusions: These studies reveal that the innate immune cells in the brain do not become tolerant to systemic
infection, but are primed instead. This may lead to prolonged and damaging cytokine production that may have a
profound effect on the onset and/or progression of pre-existing neurodegenerative disease.
Background
Humans and animals are regularly exposed to bacterial
and viral pathogens that can have a considerable impact
on our day-to-day living [1]. Upon infection, a set of im-
mune, physiological, metabolic, and behavioural responses
is initiated, representing a highly organized strategy of the
organism to fight infection. Pro-inflammatory mediators
generated in peripheral tissue communicate with the brain
to modify behaviour [2], which aids our ability to fight and
eliminate the pathogen. The communication pathways
from the site of inflammation to the brain have been
investigated in animal models and systemic challenge
with lipopolysaccharide (LPS) or double-stranded RNA
(poly I:C) have been widely used to mimic aspects of bac-
terial and viral infection respectively [3,4]. These studies
have provided evidence that systemically generated in-
flammatory mediators signal to the brain via both neural
and humoral routes, the latter signalling via the circum-
ventricular organs or across the blood brain barrier (BBB).
Signalling into the brain via these routes evokes a re-
sponse in the perivascular macrophages (PVMs) and
microglia, which in turn synthesise diverse inflammatory
mediators including cytokines, prostaglandins and nitric
oxide [2,5,6]. Immune-to-brain communication also occurs
in humans who show changes in mood and cognition fol-
lowing systemic inflammation or infection, which are asso-
ciated with changes in activity in particular regions of the
central nervous system (CNS) [7-9]. While these changes
are part of our normal homeostasis, it is increasingly evi-
dent that systemic inflammation has a detrimental effect
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in animals, and also humans, that suffer from chronic
neurodegeneration [10,11]. We, and others, have
shown that microglia become primed by ongoing
neuropathology in the brain, which increases their re-
sponse towards subsequent inflammatory stimuli, in-
cluding systemic inflammation [12,13] Similar findings
have been made in aged rodents [14,15], where it has
been shown that there is an exaggerated behavioural
and innate immune response in the brain to systemic
bacterial and viral infections, but the molecular mechan-
isms underlying the microglial priming under these condi-
tions is far from understood.
Humans and animals are rarely exposed to a single
acute systemic inflammatory event: they rather encoun-
ter infectious pathogens that replicate in vivo or are
exposed to low concentrations of LPS over a prolonged
period of time. There is limited information on the im-
pact of non-neurotrophic bacterial infections on the
CNS and whether prolonged systemic inflammation will
give rise to either a hyper-(priming) or hypo-(tolerance)
innate immune response in the brain in response to a
subsequent inflammatory stimulus.
In this study, we measured the levels of cytokines in
the serum, spleen and brain as well as assessing sickness
behaviour following a systemic bacterial infection using
attenuated Salmonella typhimurium SL3261: we com-
pared the effect to that of repeated LPS injections. We
show that Salmonella typhimurium caused acute, transi-
ent behavioural changes and a robust peripheral immune
response that peaks at day 7. Systemic inflammation
resulted in a delayed increase in cytokine production in
the brain and priming of microglia, which persisted up to
four weeks post infection. These effects were not mim-
icked by repeated LPS challenges. It is well recognised
that systemic bacterial and viral infections are significant
contributors to morbidity in the elderly [16], and it has
been suggested that primed microglia play a role in
the increased clinical symptoms seen in patients with
Alzheimer’s disease who have systemic inflammation
or infections [11,17]. We show here that systemic in-
fection leads to prolonged cytokine synthesis in the
brain and also priming of brain innate immune cells




Adult female C57BL/6 or BALB/c mice (>8 weeks old)
were obtained from Charles River, Margate, UK, and
bred in house. Mice were housed in groups of five to
ten, in plastic cages with sawdust bedding, for at least a
week before testing. Food and water were available ad
libitum. The holding room was temperature controlled
(19 to 23°C) with a 12:12 h light–dark cycle (light on at
07:00 h). Females were used as they can be group-
housed without the risk of outbreaks of aggression, and
to conform to most of our previous work. BALB/c SCID
mice were obtained from Harlan Laboratories Ltd (Harrow,
UK) and bred in house. All procedures were performed
under the authority of a UK Home Office License in ac-
cordance with the UK animals (Scientific Procedures) Act
1986, and after local ethical approval by the University of
Southampton.
Injection of LPS and infection with Salmonella
typhimurium
In experiments investigating the effects of repeated LPS
injections, mice received LPS derived from Salmonella
abortus equi (L5886, Sigma-Aldrich, Poole, UK) at a
dose of 500 μg/kg via intraperitoneal injection on three
subsequent days at the same time of day (11:00 h). This
dose of LPS was chosen for its reliable reduction in bur-
rowing and reproducible cytokine response in the brain
[12,18]. In experiments investigating the effects of a bac-
terial infection, mice were given a single intraperitoneal
injection of 106 colony-forming units (cfu) of attenuated
Salmonella typhimurium strain SL3261 (generously pro-
vided by Dr H. Atkins, DSTL, Salisbury, UK).
Burrowing and body weight
Burrowing was assessed as described previously [19].
Burrowing was measured between 1 and 3 hours after
each LPS injection or at 1 to 3 h, 1d, 7d, and 21d after
Salmonella typhimurium SL3261 infection. Body weight
was measured immediately before the burrowing assay.
Cytokine measurements
Blood samples (approximately 500 μl) were taken by car-
diac puncture in terminally anaesthetized mice and col-
lected in microfuge tubes. Samples were spun down and
serum kept at −20 °C until further use. A three milli-
metre thick coronal section containing the dorsal hippo-
campus of the right hemisphere or spleen tissue was
collected and homogenised in a TRIS buffer containing a
protease inhibitor cocktail (150 mM NaCl, 25 mM Tris,
1% Triton X-100 pH 7.4, complete protease inhibitor
cocktail (Roche Diagnostics GmbH, Mannheim, Germany)).
Samples were centrifuged for 30 minutes at 13.000 rpm
and supernatants assayed for total protein using a
Pierce BCA protein assay kit (Thermo Fisher Scientific,
Cambridge, UK). Cytokine levels in tissue and serum
samples were assessed using MSD multiplex kit for
mouse pro-inflammatory cytokines ((K15012B), Meso
Scale Discovery, Gaithersburg, MD, USA), according
to manufacturer’s instructions. Endotoxin levels in
serum samples were assessed using Cambrex’ Limulus
Amebocyte Lysate kit (Kinetic-QCL, Walkersville, MD,
USA) according to manufacturer’s instructions.
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Priming of the brain innate immune response
Naïve mice or mice that were injected intraperitoneally
with a single dose of 106 cfu Salmonella typhimurium
SL3261 were given a unilateral intracranial injection of
LPS, four weeks after the systemic Salmonella typhimur-
ium infection. The animals were anaesthetised with
a mixture of ketamine and xylazine (Ketaset/Rompun
100/10 mg/kg body weight). LPS (100 pg in 1 μl)
was injected into the dorsal hippocampus (from bregma:
anterior-posterior− 2.0 mm, lateral + 1.7 mm, depth−
1.6 mm) using a glass micropipette (Sigma-Aldrich) as
previously described [20]. At 24 h, mice were sacrificed,
transcardially perfused with 0.9% heparinised saline and
tissue collected for immunohistochemical analysis of
microglial and endothelial cell activation.
Immunohistochemistry
Immunohistochemistry was carried out on 10 μm-thick
fresh frozen tissue sections. The tissue was air dried,
fixed with cold ethanol, quenched with 1% hydrogen
peroxide in phosphate-buffered saline (PBS), and
blocked with 2% bovine serum albumin (BSA), 10% nor-
mal rabbit serum before overnight incubation with the
primary antibodies: intercellular adhesion molecule-1
(ICAM-1; YN1/1.7.4, Abcam, Cambridge, UK); vascular
cell adhesion molecule-1 (VCAM-1; MVCAM A (429),
Serotec, Oxford, UK); major histocompatibility complex
class I (MHCI; ER-HR 52, Abcam); major histocompati-
bility complex class II (MHCII; M5/114.15.2, Abcam);
CD11c (N418, a generous gift from Prof M. Glennie,
Southampton, UK); CD11b (5 C6, Serotec); CD68 (FA11,
Serotec), pan-Laminin (L9393, Sigma-Aldrich). Follow-
ing incubation with the primary antibody, sections were
washed and incubated with the appropriate biotinylated
secondary antibody (Vector Labs, Peterborough, UK).
Labelling was visualised using the avidin-biotin-peroxidase
complex (ABC, Vector Labs), using 0.015% v/v hydro-
gen peroxide as substrate and diaminobenzidine (DAB)
as chromogen (Sigma-Aldrich). For immunofluores-
cence, sections were incubated with 4% BSA, before
overnight incubation with unconjugated primary anti-
bodies and labelling was visualised by Alexa Fluor
488 or Alexa Fluor 546 conjugated secondary antibodies
(Invitrogen, Paisley, UK). Mounted sections were cover-
slipped using Prolong Gold antifade reagent with
4',6-diamidino-2-phenylindole (DAPI) (Invitrogen). Analysis
of the immunohistological staining was performed using a
Leica DM5000 microscope (Leica Micosystems, Milton
Keynes, UK).
Quantification of immunohistochemistry images
Images were captured at 20x optical zoom using QWin
software by Leica Microsystems. All images were cap-
tured using identical exposure limit, gain, saturation,
shading and filter. DAB staining within the images was
identified using ImageJ with the Colour Deconvolution
plugin to eliminate haematoxylin counterstain. Image
threshold limit was lowered to a set level to remove
background noise and kept constant for all images.
Images were then converted to binary and the area of
staining was measured: the fold increase in stained area
was calculated using the contralateral hemisphere of
LPS-injected mice as the control.
Statistical analysis
Cytokine production was analysed by one-way analysis
of variance (ANOVA) followed, if significant, by Tukey’s
multiple comparison test using Graphpad Prism soft-
ware (GraphPad Software Inc., La Jolla, CA, USA). Bur-
rowing behaviour and body weight measurements were
analysed by repeated ANOVA measures followed, if sig-
nificant, by Tukey’s multiple comparison test using
Graphpad Prism software (GraphPad). Immunohisto-
chemistry results were analysed by two-way ANOVA fol-
lowed by Bonferroni post-test using Graphpad Prism
software (GraphPad). Values were expressed as means ±
SEM. A P value < 0.05 was considered to indicate signifi-
cant difference. Full ANOVA statistics are combined in
Table S1 in Additional file 1.
Results
The effect of repeated LPS challenges on peripheral and
central cytokines
To investigate immune-to-brain communication follow-
ing multiple systemic LPS challenges, we injected LPS
intraperitoneally on three consecutive days and after
each LPS challenge we measured burrowing activity and
cytokines in the serum, spleen and brain. The first LPS
challenge led to an increase in protein levels of
interferon-gamma (IFN-γ), interleukin-1 beta (IL-1β)
and IL-12 in the serum (Figure 1A, IFN-γ 7.1-fold
P < 0.001, IL-1β 20-fold P < 0.001, IL-12 1.6-fold not sig-
nificant (n.s.)) and the spleen (Figure 1B, IFN-γ 11.5-fold
P < 0.001, IL-1β 18-fold P < 0.001, IL-12 5.8-fold
P < 0.001). Similar changes were observed for IL-6,
tumor necrosis factor-alpha (TNF-α), and keratinocyte-
derived chemokine (KC) (data not shown). Upon the
second and third challenge, serum and spleen levels of
IFN-γ, TNF-α and IL-12 no longer increased in response
to LPS, demonstrating induction of endotoxin tolerance
(Figure 1A-B). In contrast to the periphery, protein
levels of IFN-γ, IL-1β, IL-12 (Figure 1C) in the brain did
not significantly increase relative to saline controls after
the first systemic challenge with LPS, while a second
challenge significantly increased the protein levels of
IL-1β and IL-12 (Figure 1C, IL-1β 235-fold P < 0.001,
IL-12 1.9-fold P < 0.05) . The third dose of LPS led to
a reduced synthesis of IL-1β and IL-12 in the brain
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(Figure 1C, IL-1β 2.6-fold reduction P < 0.001, IL-12
1.7-fold reduction n.s.), similar to that observed in the per-
iphery after multiple LPS challenges. Brain IFN-γ levels
remain below 1 pg/mg protein, despite increased levels
(up to 104 pg/ml) in the serum.
Increased systemic cytokine levels following LPS chal-
lenge has been associated with transient changes in sick-
ness behaviour and body weight [18,21]. We observed
that, despite a reduction in systemic cytokine levels, bur-
rowing behaviour is reduced to below 30% (P < 0.001) of
baseline burrowing upon each peripheral challenge with
LPS (Figure 1D). The first LPS challenge induces a
robust change in body weight measured 24 h after the
injection (Figure 1D, P < 0.001). A second or third
challenge does not lead to a further significant decrease
in body weight (Figure 1D).
The effect of a bacterial infection on peripheral and
central cytokines
LPS binds to and triggers TLR4 signalling in innate im-
mune cells, and only mimics certain aspects of a bacter-
ial infection. Therefore, we next measured cytokines
levels in the periphery and brain following a non-
neurotropic bacterial infection and assessed whether the
cytokine levels correlate with behavioural and metabolic
changes. Mice were inoculated with a sublethal dose of
S. typhimurium strain SL3261 and cytokines levels in
serum, spleen and brain were measured at 1, 7, 14 and
Figure 1 Immune adaptation in response to multiple LPS challenges. (A-C) Cytokine production in response to repeated systemic
challenges with LPS. Levels of protein expression of inflammatory cytokines in serum (A), spleen (B), and brain (C) in saline or LPS- injected mice.
LPS challenges were given on three consecutive days, with 24 h between each injection. Cytokine levels were measured 3 h after each LPS
injection and compared to cytokine levels in naïve mice. (D) Changes in burrowing behaviour and body weight upon multiple LPS challenges.
Error bars represent SEM from five animals per time point (P< 0.05 (*), P< 0.01 (**), P< 0.001 (***) versus naïve control). This experiment was
repeated three times with similar results.
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21 days. Burrowing, appearance and body weight was
assessed on the day of infection and daily thereafter. At
24 h after SL3261 injection, we could not detect
increased levels of pro-inflammatory cytokines in the
periphery, while at day 7 protein levels of IFN-γ, IL-1β
and IL-12 were increased in both serum (Figure 2A,
IFN-γ 532-fold P < 0.001, IL-1β 55-fold n.s., IL-12 2.3-
fold P < 0.01) and spleen (Figure 2B, IFN-γ 44-fold
P < 0.001, IL-1β 4.3-fold P < 0.01, IL-12 1.8-fold n.s.) tis-
sue. Serum levels of IFN-γ (959 ± 193 pg/ml) and IL-1β
(38.2 ± 26.4 pg/ml) peaked at day 7, and circulating levels
of IL-12 remained significantly elevated up to 21 days
(3.6 ± 0.3 ng/ml, 4.4 ± 0.5 ng/ml, 3.9 ± 0.4 ng/ml at days
7, 14, and 21, respectively). In spleen tissue, we detected
increased levels of all three cytokines from day 7 up to
day 21 (Figure 2B). In the brain, the protein levels of the
pro-inflammatory cytokines IL-1β, IL-12 (Figure 2C) and
IL-6 (data not shown), were comparable to control levels
when measured at day 7 post-infection, but levels of
these cytokines increased gradually to become signifi-
cantly increased at 21 days post-infection (Figure 2C,
IL-1β 4.7-fold P< 0.05, IL-12 4.4-fold P< 0.05). Brain
levels of IFN-γ remained below 1 pg/mg protein during
the entire three-week period post-infection (Figure 2C).
Burrowing was significantly reduced to 30% (P < 0.001)
of baseline when measured 1 to 3 h after administration
Figure 2 Immune adaptation in response to SL3261 infection. (A-C) Cytokine production in response to systemic challenge with Salmonella
typhimurium SL3261. Levels of protein expression of inflammatory cytokines in serum (A), spleen (B), and brain (C) in naïve non-infected or
SL3261-infected mice. Cytokine levels were measured at 1, 7, 14, and 21 days after the infection with 106 cfu SL3261 and compared to cytokine
levels in naïve mice. (D) Changes in burrowing behaviour, body weight and serum endotoxin levels upon SL3261 infection. Behaviour
experiments were carried out with n = 5 per time point. Error bars represent SEM from five animals per time point (P< 0.05 (*), P< 0.01 (**),
P< 0.001 (***) versus naïve control). This experiment was repeated two times with similar results.
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of SL3261, and after 24 h, these changes reverted back
to baseline levels (Figure 2D). Mice showed transient
changes in appearance during 1 to 3 h (for example,
hunched posture, piloerection), which were no longer
observed 24 h after infection. The changes in burrowing
and appearance coincided with endotoxin levels in the
serum of the animals (Figure 2D). Inoculation of mice
with SL3261 resulted in a robust loss of body weight
(Figure 2D, P < 0.001) and this was restored to baseline
levels at day 7 post-infection (Figure 2D). At this stage,
the lymphoid organs (spleen and draining lymph nodes)
had markedly increased their size to approximately five
times their original size (data not shown). These data
show that a bacterial infection induces a strong immune
activation in the periphery, and a delayed but long-
lasting cytokine response in the brain. The increased
levels of cytokines in the periphery and brain did not
correlate with anhedonia behaviour assessed by bur-
rowing (Figure 2).
Cellular changes in the brain
To further characterise the impact of a systemic bacter-
ial infection on the brain, we examined coronal sections
between 1.8 and 2 mm posterior to bregma for a range
of molecules typically expressed on activated endothe-
lium (ICAM-1, VCAM-1, MHCI, MHCII) or microglia/
macrophages (CD68, CD11b, MHCI, MHCII) at 1, 7, 14
and 21 days following infection with SL3261.
Changes in cerebral vasculature
The most profound change on the cerebral vasculature
was the up-regulation of MHCI and MHCII. Low levels
of MHCI can be detected on the cerebral vasculature of
naïve control mice (Figure 3A), while MHCII is un-
detectable (Figure 3E). At 24 h post-infection, no
changes in expression levels of these molecules were
observed (Figure 3B and F). However, from day 7 after
infection the cerebral vasculature, including veins, arter-
ies and capillaries, as judged by their morphology and
size, stained positive for both MHCI and MHCII
(Figure 3C and G). Increased expression of MHCII
molecules was conspicuous in the cortex and hippocam-
pus (Figure 4), and levels remained readily detectable on
the cerebral vasculature throughout the three-week time
course. The administration of a single LPS challenge did
not induce MHCII on the brain vasculature, measured
at day 3 and 7, nor did multiple LPS challenges,
measured 3 h after the final injection (data not shown).
The cell adhesion molecules VCAM-1 and ICAM-1
were both expressed at low levels on the brain vascula-
ture of naive mice (Figure 3I and M). Increased expres-
sion of VCAM-1 and ICAM-1 was observed from 24 h
post-infection (Figure 3J and N), but the most promin-
ent changes were observed at day 7 after infection
(Figure 3K and O). At three weeks, the expression levels
of the adhesion molecules had decreased to similar
levels as observed at day 1 (Figure 3L and P).
Changes in parenchymal cells
Analysis of microglia/macrophage markers suggested
that microglia also respond to a systemic challenge of
(See figure on previous page.)
Figure 3 Kinetics of immune marker expression after SL3261 infection. Immune markers of vascular endothelial cells and microglia/
macrophages (MHCI (A-D), MHCII (E-H), ICAM-1 (I-L), VCAM-1 (M-P), CD11b (Q-T), and CD68 (U-X)) at 1d (B, F, J, N, R, V), 7d (C, G, K, O, S, W),
and 21d (D, H, L, P, T, X) after a systemic challenge with Salmonella typhimurium SL3261 compared to naïve non-infected mice (A, E, I, M, Q, U).
Representative images from the dorsal lateral geniculate nucleus of the thalamus are shown. Phenotype analysis was carried out with n = 3 mice
per time point. Scale bar = 50 μm.
Figure 4 MHCII expression in the brain after systemic SL3261
infection. Brains from naïve mice (A) and mice that were infected
with SL3261, 7 days previously (B) were cut through the dorsal
hippocampus and thalamus and analysed for MHCII expression. The
image of the naïve brain was overlaid with an outline of the brain
and the cell fields of the dorsal hippocampus to aid the orientation
within the image.
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SL3261. At day 7 after infection, we observed a modest
increase in CD11b expression in mice inoculated with
SL3261 (Figure 3S), when compared to naïve control
mice (Figure 3Q). Infection of mice with SL3261 also led
to increased expression of CD68 in perivascular macro-
phages and microglia (Figure 3W), while in naïve mice,
CD68 is conspicuously expressed in perivascular macro-
phages (Figure 3U). The changes in CD11b and CD68
expression returned to baseline levels at three weeks
(Figure 3T and X). The morphology of the microglia
remained ramified with fine processes, despite changes
in CD11b and CD68 expression.
Cellular changes in the brain of SCID mice
To determine whether the phenotypic changes of cere-
bral vascular cells and microglia are dependent on innate
immune responses, we compared the cellular changes in
the brain of BALB/c SCID and BALB/c control mice,
following systemic SL3261 infection. As seen in C57BL/
6 J mice, we observed increased expression of MHCII
(Figure 5A and B) and MHCI (Figure 5C and D) on
cerebral vascular cells in both BALB/c mouse strains,
analysed 5 days post-infection. In addition, no apparent
differences were found in CD11b immunoreactivity on
microglia in the brain parenchyma between SCID or
control mice infected with SL3621 (Figure 5E and F).
Priming of the brain innate immune response
The immunohistochemical analysis suggests that micro-
glia/macrophages become transiently activated after in-
fection with SL3261, and appear to return to their
original morphology and phenotype by three weeks.
However, brain cytokines remain elevated, suggesting an
altered innate immune response in the brain. To investi-
gate whether the innate immune cells in the brain are
‘primed’ by systemic infection, we challenged mice with
a focal intrahippocampal, unilateral injection of 100 pg
of LPS four weeks after the initial systemic infection. In
naïve animals, LPS injection led to a small, but detect-
able up-regulation of the expression of a number of
myeloid markers on microglia and macrophages
(Figure 6A, E, and I) compared to the uninjected site
(Figure 6B, F, and J). A few microglia displayed thicker
processes and hypertrophic cell bodies (Figure 6F).
Quantification of the data show that microglia in the
LPS-injected hemisphere of naïve mice exhibit a 2-fold
increase in CD68 expression (F(1,10) = 7.09 P= 0.0238)
relative to uninjected brain (Figure 7) and SL3261-
treated animals showed a 2.6-fold increase of CD68
(F(1,10) = 7.09 P< 0.05) following an intracerebral injection
of LPS and displayed an activated morphology with
retracted processes, but these changes were not different
from similarly treated naïve mice (F(1,10) = 0.53 n.s.). Simi-
lar results were observed for CD11b expression levels
(Figure 7). In contrast, focal injection of LPS into the brain
of previously SL3261-infected animals led to higher ex-
pression levels of CD11c (Figure 6A-D and 7, interaction:
F(1,12) = 5.59 P< 0.05), MHCII (Figure 6L and 7, inter-
action: F(1,14) = 10.0 P< 0.01), and MHCI (Figure 7, inter-
action: F(1,14) = 1.11 n.s.). Microglia or macrophages in the
parenchyma showed expression of CD11c, which was not
detected on microglia of naïve mice (Figure 6A-D). In
addition, there appeared to be an increased number of





Figure 5 Immune marker expression in SCID mice after
systemic infection with SL3261. Immune markers of the vascular
endothelial cells and microglia/macrophages (MHCII (A-B), MHCI
(C-D), and CD11b (E-F)) in BALB/c (A, C, E) or BALB/c SCID (B, D, F)
mice measured at day 5 after a systemic infection with SL3261. Due
to more severe clinical symptoms in the SCID mice following
SL3261, mice were sacrificed at day 5. BALB/c wild-type mice were
analysed at the same time point for comparison. The images are
representative examples of immune marker activation of n = 5
animals per group. Scale bar = 50 μm.
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treated mice, suggesting possible recruitment of myeloid
cells from the circulation (Figure 6D). The cerebral vascu-
lature of mice infected with SL3261 four weeks previous
to the LPS challenge remained positive for MHCII
(Figure 6K and O) and intracerebral injection of LPS
induced MHCII expression on parenchymal microglia/
macrophages. This observation was confirmed by a double
staining with laminin to differentiate MHCII +microglial
cells from MHCII + endothelial cells of the vasculature
(Figure 6P).
I






Figure 6 Primed innate immune response in the brain following a systemic bacterial infection. Phenotypic changes after intracerebral
injection of 100 pg of LPS in naïve mice (A, B, E, F, I, J, M, N) or mice pretreated with SL3261 (C, D, G, H, K, L, O, P). Representative images of
immune marker expression (CD11c (A-D), CD68 (E-H), MHCII (I-L) in the injected hemisphere (B, D, F, H, J, L, N, P) or contralateral site are shown.
Panels M-P show a double immunofluorescent stain for MHCII (green) and laminin (red). n = 5 animals per group, black scale bar = 50 μm, white















Figure 7 Immune marker expression after intracerebral injection of LPS. LPS was injected intracerebrally into one hemisphere of naïve mice
or mice that had been infected with SL3261 four weeks previously. The figure shows the fold increase and SEM of immune marker expression
over the naïve uninjected section. Data was analysed by two-way ANOVA and significant interaction is shown (P< 0.05 (*), P< 0.01 (**), n = 4-5).
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Discussion
A systemic infection activates multiple physiological
pathways that aid in the elimination of the pathogen and
recovery of the host. These include innate and acquired
immune responses as well as the activation of communi-
cation pathways between the immune system and the
brain to co-ordinate essential metabolic and behavioural
changes. The mechanisms underlying immune-to-brain
communication following a single dose of LPS are well
described [22], but information on real bacterial infec-
tions restricted to peripheral tissues is still sparse. This
is surprising, given how frequently systemic infections
occur in the population and their potential to exacerbate
brain disease [11,23]. In the current study, we compared
the cytokine response in the periphery and the brain of
mice that received either multiple doses of S. abortus
equi-derived LPS or a bacterial infection with attenuated
Salmonella typhimurium (SL3261). A single LPS injec-
tion induced high systemic cytokine levels with asso-
ciated behavioural changes, but no detectable levels of
IL-1β and IL-12 protein in the brain. A second LPS chal-
lenge induced significant protein levels of pro-
inflammatory cytokines in the brain, despite reduced
peripheral cytokine expression. A subsequent third chal-
lenge with LPS resulted in a reduced synthesis of cyto-
kines both systemically and in the brain, indicative of
tolerance in both compartments. The levels of cytokines
did not correlate in a simple way, with a deficit in bur-
rowing behaviour, a measure of anhedonia, which was
reduced after each LPS challenge, suggesting that the
burrowing is not controlled by cytokines alone and not
altered during endotoxin tolerance.
When we assessed the effect of a bacterial infection,
we observed acute behavioural changes that rapidly
resolved. Despite these transient changes in behaviour,
there was clear evidence of sustained immune activation
in both the periphery and the brain. Cytokines in the
serum, including IFN-γ and IL-1β were significantly
increased at day 7, and raised levels of IL-1β and IL-12
in the spleen were present up to three weeks post-infec-
tion. In addition to cytokine production, we observed
up-regulation of ICAM-1, VCAM-1, MHCI, and MHCII
on the cerebral vasculature and increased levels of
CD11b and CD68 on microglia. These observations
demonstrate that repeated systemic LPS injections and a
bacterial infection both result in immune activation in
the brain but with different kinetics, different magnitude
and differential cell involvement in the brain including
endothelium, perivascular macrophages and microglia.
Priming versus tolerance
Mounting an immune response to infection is essential
for survival, but excessive or prolonged inflammatory
responses can result in bystander tissue damage and
septic shock. One mechanism to regulate innate immune
responses is endotoxin tolerance, which is characterised
by a transient state of cellular, metabolic and behavioural
hypo-responsiveness to subsequent or chronic systemic
infections [24]. Stimulation of TLR4 results in signalling
of nuclear factor kappa B (NFκB), which induces gene
transcription of pro-inflammatory cytokines including
TNF-α, IL-12 and IL-1β, while a second stimulation with
LPS results in a repression of these genes leading to
reduced lethality, fever, and anorexia [25-27]. It has been
shown that LPS-induced cytokine expression still occurs
in the brain during endotoxin tolerance, when cytokines
in the periphery are no longer induced [28,29] and our
results are in agreement with these observations. Fag-
gioni et al. suggested that tolerance induction in the
brain requires direct stimulation of TLR4-expressing
cells. This is supported by experiments where LPS was
directly injected into the brain, showing reduced TNF-α
production upon restimulation [29]. Other studies have
shown that systemic exposure to LPS induced endotoxin
tolerance to a different bacterial strain [30]. These
changes were independent of peripheral cytokine levels
and long lasting, as tolerance was still observed 3 weeks
after the first challenge. However, it should be noted that
the high dose of LPS (1 mg/kg) may have altered BBB
permeability allowing exposure of perivascular macro-
phages or microglia to LPS. Although microglia are a
likely source of increased pro-inflammatory cytokines
following a systemic infection, we cannot rule out other
cell types. Endothelial cells express functionally signifi-
cant amounts of TLR4 and are capable of producing in-
flammatory cytokines and chemokines [31]. In vitro
studies show that cytokines are continuously produced
by endothelial cells after repeated LPS treatment [32],
which implies that endothelial cells do not become toler-
ant to LPS. Recent studies have suggested that epigenetic
changes play a role in endotoxin tolerance [33,34], and
that gene selective programming and histone modifica-
tion determines the threshold for subsequent cell activa-
tion [33-35]. In contrast to most macrophages in the body,
microglia are kept in a quiescent state and it is possible that
exposure to LPS induces chromatin remodelling, which
then allows further activation by a secondary challenge.
Similar observations have been made by Stalder et al. [36],
who demonstrated that microglia were the major producers
of IL-12 in the brain after a second systemic LPS challenge
in contrast to spleen where high levels of IL-12 were pro-
duced after the first challenge. The degree of tolerance may
involve numerous variables including the strain of LPS used
in the first and subsequent challenges [30] and the delay be-
tween the challenges.
Microglia and macrophages in the brain parenchyma
of SL3261-pretreated mice showed increased levels of
MHCII and CD11c, after intracerebral LPS challenge,
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which was not seen in similarly challenged naïve mice. It
has been reported that microglia express CD11c under
inflammatory conditions, therefore CD11c positive cells
in SL3261-pretreated and LPS-restimulated brain can be
both activated microglia and/or recruited macrophages
from the circulation [37,38]. Previous studies investigat-
ing the impact of the environment on the immune re-
sponse of the brain parenchyma to a viral vector and
reporter gene synthesis showed a similar hyper-
responsive effect. Animals exposed to a conventional
animal house environment gave a more robust inflam-
matory response to the viral vector and reduced reporter
gene synthesis when compared to animals raised and liv-
ing in a specific-pathogen-free environment [39]. The
fact that the innate immune response appears to be
influenced by prior exposure many days or even weeks
previously is suggestive of an innate immune memory.
Netea et al. [40] have reviewed this phenomenon in
plants, invertebrates and vertebrates and suggest the ex-
istence of a trained immunity, mediated by epigenetic
changes of the immune system. Furthermore, recent
observations show that early-life infections can alter the
threshold of IL-1β production in the hippocampus via
long-lasting priming of microglia [41]. Based on these
observations we hypothesise that epigenetic changes
may control the innate priming observed in our model.
The impact of S. typhimurium on the CNS, innate versus
adaptive immunity
The immune response to systemic infection with wild-
type S. typhimurium and its attenuated aroA mutant
strain SL3261 is well documented [42,43]. Macrophages
and neutrophils play a key role in the initial response to
infection by secreting the cytokines IL-12, IL-18, and
TNF-α. IL-12 contributes to the establishment of a pro-
tective T helper 1 (Th1) immune response and mediates
host resistance by inducing IFN-γ synthesis in natural
killer (NK)-cells and macrophages [44-46]. Clearance of
the bacteria requires MHC-II restricted, SL3261-specific
CD4+ T cells that become detectable at 7 days post-
infection [42]. These immune responses are not
observed after multiple LPS challenges, and a major
finding of our study is to highlight that repeated LPS
challenges poorly mimic the peripheral immune re-
sponse to a bacterial infection. Our study shows
increased levels of IL-12 up to three weeks post-
infection and increased levels of IFN-γ in serum and
spleen that peak at day 7, while repeated LPS induced a
blunted cytokine response in the periphery and did not
result in increased expression of MHCI and MHCII on
cerebral endothelial cells. We detected acute changes in
burrowing that normalized after 24 h. The behavioural
changes coincided with detectable circulating levels of
LPS in the serum, making it possible that systemic LPS
induced the behavioural changes directly by engaging
TLR4 on cerebral endothelial cells.
Long-term consequences of systemic inflammation
A striking effect following systemic infection with
SL3261 was the prolonged up-regulation of MHCI and
MHCII expression on the cerebral vasculature. To our
knowledge, this is the first study to report these long-
lasting alterations to cerebral vasculature in response to
non-neurotropic bacterial infection. IFN-γ is a major
regulator of MHC molecules on cerebral endothelium
and it has been shown that IFN-γ up-regulates MHCII
on cerebral endothelium in culture [47] and following
infection with Toxoplasma gondii (46). Our data using
SCID mice suggest that innate immune cells, such as
macrophages or NK cells, are the likely cellular source
of this cytokine. The functional consequences of
increased MHCI and MHCII expression on cerebral
endothelium following SL3261 are unknown. One possi-
bility is that increased expression of MHC molecules
contributes to a protective mechanism to regulate im-
mune activation in the CNS, by inducing T cell tolerance
in the absence of co-stimulatory molecules such as
CD40 or CD80 (data not shown). A similar lack of co-
stimulatory molecules has been shown in vitro following
stimulation of primary human endothelial cells [48]. It
has also been shown that MHCI expression on endothe-
lium can act as a molecular address for CD8 cell inva-
sion into the brain parenchyma without activation of the
cells [49].
Systemic infection with Mycobacterium tuberculosis
(Bacillus Calmette-Guérin, BCG) leads to acute changes
in locomotor activity, followed by depressive symptoms
at 7 days that coincide with an increase in indoleamine
2,3-dioxygenase (IDO) and increased mRNA levels of
IFN-γ, IL-1β and TNF-α in the brain [50,51]. BCG and
S. typhimurium infect their host cells in a similar way
and it is likely that they share similar immune-to-brain
communication pathways.
Conclusions
Our study shows that systemic infection with non-
neurotropic S. typhimurium has long-term consequences
for homeostasis in the CNS, due to changes in the cere-
bral vasculature and priming of the innate immune re-
sponse. It is well recognised that systemic bacterial and
viral infections are significant contributors to morbidity
in the elderly. A number of studies have described mor-
phologically activated microglia in the aged rodent and
human brain with increased levels of MHCII and CD68
expression [52,53]. Altered expression of immunoregula-
tory molecules, such as CD200 or fractalkine on neurons
is one explanation for these microglial phenotype
changes. As an alternative or additional factor, we
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propose that the morphologically activated microglia of
the aged brain may be primed by low-grade systemic in-
flammation experienced throughout life.
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